Company: LCTX
Filing Date: 2025-03-10
Form Type: 10-K
Source: 0000950170-25-036309
Chunk: 233

Company: Lineage Cell Therapeutics, Inc.
Filing Date: 2025-03-10
Form: 10-K
Item: Item 7
Chunk 233
---
    2024

    2023

    OpRegen®
     
    $
    6,081

    $
    5,488

    49
    %

    35
    %

    OPC1

    3,491

    6,214

    28
    %

    39
    %

    ANP1

    2,200

    2,012

    18
    %

    13
    %

    PNC1

    156

    487

    1
    %

    3
    %

    RND1

    394

    754

    3
    %

    5
    %

    Other programs and non-program expenses

    150

    750

    1
    %

    5
    %

    Total research and development expenses
     
    $
    12,472

    $
    15,705

    100
    %

    100
    %

Research and development expenses. For the twelve months ended December 31, 2024, the $3.2 million year-over-year decrease in total research and development expenses is mainly attributable to: (i) a $2.7 million decrease for our OPC1 program as compared to the prior year primarily due to delays in obtaining clearance from the FDA to 

87

proceed with the DOSED study; (ii) a $0.5 million decrease for our preclinical programs; (iii) a $0.6 million decrease for our other research and development programs; and (iv) partially offset by a $0.6 million increase for our OpRegen program.

General and administrative expenses. For the twelve months ended December 31, 2024, the $0.9 million year-over-year increase in general and administrative expenses was primarily attributable to (i) a $0.6 million increase in stock-based compensation; (ii) a $0.4 million increase in personnel costs; and (iii) partially offset by a $0.1 million overall decrease in costs incurred for services provided by third parties.

Other Income and Expenses, Net

The following table shows the amount of other income (expenses), net, during the year ended December 31, 2024 and 2023 (in thousands):

    Year Ended December 31,

    Dollar Increase

    Percent Increase

    Other income (expenses)
     
    202